|1.||Takaba, Katsumi: 1 article (01/2009)|
|2.||Manabe, Haruhiko: 1 article (01/2009)|
|3.||Kobayashi, Katsuya: 1 article (01/2009)|
|4.||Takashima, Yuko: 1 article (01/2009)|
|5.||Takada, Chie: 1 article (01/2009)|
|6.||Nosaka, Yukino: 1 article (01/2009)|
|7.||Harada, Daisuke: 1 article (01/2009)|
|3.||Atopic Dermatitis (Atopic Eczema)
01/01/2009 - "The present results suggest that KF66490 has excellent potential as an oral medicine for the treatment of atopic dermatitis."
01/01/2009 - "To evaluate efficacy of KF66490 in atopic dermatitis (AD) models, on skin inflammation induced by repeated application of 2,4,6-trinitro-1-chlorobenzene (TNCB) on ear in BALB/c mice and on spontaneously AD-like skin diseases in NC/Nga mice. "
01/01/2009 - "In addition, KF66490 significantly suppressed the development of dermatitis in NC/Nga mice on all observation days, except for 5 and 6 weeks after the first dose. "
01/01/2009 - "In the TNCB-induced dermatitis model, KF66490 significantly inhibited the increase in ear thickness and interleukin (IL)-4 and IL-1beta levels in the ear. "
01/01/2009 - "Effect of orally administered KF66490, a phosphodiesterase 4 inhibitor, on dermatitis in mouse models."
|1.||Picryl Chloride (Trinitrochlorobenzene)
|2.||Type 4 Cyclic Nucleotide Phosphodiesterases